EC Pharmacology and Toxicology

The anti-inflammatory and pain-relieving effects of aspirin have been known to science and widely used for quite some time. The list of applications for this compound continues to grow, and it now includes anti-inflammatory and anti-platelet activities. It is not necessary to place an undue amount of emphasis on the part it plays in cardiovascular diseases because of this. This study aimed to conduct a literature review on the topic of the toxicity that can be caused by the use of aspirin, with the purpose of answering the following question: The toxicity that it primarily causes over a prolonged period of time has an effect on the upper gastrointestinal system. It is also capable of causing acute toxicity if consumed in sufficient quantities to reach that threshold. When everything is taken into account, the significance of aspirin and the widespread use of the drug should not be used as an excuse to disregard the drug's potential for toxicity. Instead, treating physicians should conduct clinical evaluations of their patients in addition to any necessary blood, liver, and kidney function tests.

Keywords: Aspirin; Toxicity; Liver Function Test; Kidney Function Test; Chronic Toxicity

1. Awtry EH and Loscalzo J. “Aspirin”. Circulation10 (2000): 1206-1218.
2. Smith WL. “Prostanoid biosynthesis and the mechanism of action”. American Journal of Physiology 263 (1992): F118F191.
3. Williams CS and DuBois RN. “Prostaglandin endoperoxide synthase: why two isoforms?” American Journal of Physiology 270 (1996): G393-G400.
4. Breddin K., et al. “The German-Austrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo, and phenprocoumon in secondary prevention of myocardial infarction”. Circulation5 (1980): V63-V72.
5. Morita I., et al. “Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2”. Journal of Biological Chemistry 270 (1995): 10902-10908.
6. Kujubu DA., et al. “TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue”. Journal of Biological Chemistry 266 (1991): 12866-12872.
7. Törüner M. “Aspirin and gastrointestinal toxicity”. Anadolu Kardiyoloji Dergisi2 (2007): 27-30.
8. Lavie CJ., et al. “Upper Gastrointestinal Toxicity Associated with Long-Term Aspirin Therapy: Consequences and Prevention”. Current Problems in Cardiology5 (2017): 146-164.
9. ND Yeomans., et al. “Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin”. Alimentary Pharmacology and Therapeutics 22 (2005): 795-801.
10. Y Niv., et al. “Endoscopy in asymptomatic minidose aspirin consumers”. Digestive Diseases and Sciences 50 (2005): 78-80.
11. JL Goldstein., et al. “Aspirin use in secondary cardiovascular protection and the development of aspirin-associated erosions and ulcers”. Journal of Cardiovascular Pharmacology 68 (2016): 121-126.
12. A Barkun and G Leontiadis. “Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease”. The American Journal of Medicine 123 (2010): 358-366.
13. LA Garcia Rodriguez., et al. “Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies”. PLoS One 11 (2016): e0160046.
14. DL Bhatt., et al. “ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents”. Circulation 118 (2008): 1894-1909.
15. C Sostres and A Lanas. “Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?” Drugs 71 (2011): 1-10.
16. JJ Sung., et al. “Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial”. Annals of Internal Medicine 152 (2010): 1-9.
17. S Hernandez-Diaz and LA Garcia Rodriguez. “Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications”. BMC Medicine 4 (2006): 22.
18. A Lanas., et al. “Aspirin cardiovascular/gastrointestinal risk calculator—a tool to aid clinicians in practice”. Alimentary Pharmacology and Therapeutics 37 (2013): 738-748.
19. Euwema MS and Swanson TJ. “Deadly Single Dose Agents”. Stat Pearls [Internet]. StatPearls Publishing; Treasure Island (FL) (2022).
20. James T., et al. “Chemical warfare agent simulants for human volunteer trials of emergency decontamination: A systematic review”. Journal of Applied Toxicology1 (2018): 113-121.
21. Ciejka M., et al. “Drug Toxicities of Common Analgesic Medications in the Emergency Department”. Clinics in Laboratory Medicine4 (2016): 761-776.
22. Patel SR. “Toxicologic emergencies in the intensive care unit: management using reversal agents and antidotes”. Critical Care Nursing Quarterly4 (2013): 335-344.
23. Shively RM., et al. “Acute salicylate poisoning: risk factors for severe outcome”. Clinical Toxicology3 (2017): 175-180.
24. Juurlink DN., et al. “Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup”. Annals of Emergency Medicine2 (2015): 165-181.